135 related articles for article (PubMed ID: 17317832)
1. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Fakih MG; Trump DL; Muindi JR; Black JD; Bernardi RJ; Creaven PJ; Schwartz J; Brattain MG; Hutson A; French R; Johnson CS
Clin Cancer Res; 2007 Feb; 13(4):1216-23. PubMed ID: 17317832
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
Muindi JR; Johnson CS; Trump DL; Christy R; Engler KL; Fakih MG
Cancer Chemother Pharmacol; 2009 Dec; 65(1):33-40. PubMed ID: 19396601
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G
Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
6. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC;
J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
Muindi JR; Peng Y; Potter DM; Hershberger PA; Tauch JS; Capozzoli MJ; Egorin MJ; Johnson CS; Trump DL
Clin Pharmacol Ther; 2002 Dec; 72(6):648-59. PubMed ID: 12496746
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
[TBL] [Abstract][Full Text] [Related]
11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Gross ME; Leichman L; Lowe ES; Swaisland A; Agus DB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):273-80. PubMed ID: 22002543
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Padda SK; Chhatwani L; Zhou L; Jacobs CD; Lopez-Anaya A; Wakelee HA
Anticancer Drugs; 2013 Aug; 24(7):731-5. PubMed ID: 23552470
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
16. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer.
Beer TM; Javle M; Lam GN; Henner WD; Wong A; Trump DL
Clin Cancer Res; 2005 Nov; 11(21):7794-9. PubMed ID: 16278401
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hoekstra R; Dumez H; Eskens FA; van der Gaast A; Planting AS; de Heus G; Sizer KC; Ravera C; Vaidyanathan S; Bucana C; Fidler IJ; van Oosterom AT; Verweij J
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6908-15. PubMed ID: 16203782
[TBL] [Abstract][Full Text] [Related]
20. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]